Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04171570
Other study ID # T133E3
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 10, 2019
Est. completion date December 28, 2021

Study information

Verified date May 2022
Source Terumo Europe N.V.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to demonstrate the superiority of Distal Radial Access (DTRA) to Conventional Transradial Access (CTRA) regarding forearm radial artery occlusion (RAO). This trial plans to include 1300 patients in around 12 locations around the world (11 participating sites in Europe and 1 participating site in Japan).


Description:

DISCO RADIAL is a prospective, global, open label, multi-centre randomized controlled trial with plan to include approximately 1300 patients on who transradial coronary angiography and/or intervention is performed. The patients will be randomized in 1:1 ratio to either Distal Transradial Artery Access (DTRA) or Conventional Transradial Access (CTRA) arm. In both arms 6Fr Glidesheath Slender (GSS) will be used as access sheath. The sponsor will work in accordance with standard operating procedures (SOP) and the Monitoring Plan in order to ensure adherence to the CIP and applicable regulations at the investigational sites. The Monitoring Plan is built according to a risk-based monitoring approach and describes the level of source data verification to be performed by the monitors. Risk-based monitoring approach uses all available means to supervise the trial (central monitoring, remote monitoring and on-site monitoring), focusing in critical data points and issues ensuring that adequate monitoring (central, remote and on-site) at each site is completed to ensure protection of the rights and safety of the subjects and the quality and integrity of the data collected and submitted. The sponsor shall provide training and the necessary guidelines to assist each investigational site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality and avoid missing information in the eCRF, edit checks are designed during database development. In addition, Sponsor's CRA and Data Management team will be responsible to review the data and raise queries accordingly into the eCRF. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements. The following analysis sets will be considered for the statistical analysis : As Treated Population This population includes all patients who were treated and undergo the studied procedure. Patients will be assigned to the study treatement groups according to the actual received treatement. Intention-To-Treat Population This population includes all patients who have been randomized to a treatement. Patients will be assigned to the study treatement groups according to the treatement to which they have been randomized. Per-Protocol Population This population includes all patients who were treated and undergo the studied procedure, excluding all patients with major violations to the protocol (e.g. wrong inclusion, missing data, mis-randomization, crossover, drop off before discharge). Patients will be assigned to the study treatement groups according to the treatement to which they have been randomized. All the protocol deviations will be reported in statistical report. Assuming a rate of forearm RAO of 1% in DTRA and 3.5% in CTRA based on on two-sided alpha = 0.050 and power = 80%, 1:1 randomization needs 551 patients for each group to detect statistically significant differences in forearm RAO proportions. Then, given the crossover rate of 10% and the drop out rate of 5% for both group, at least 648 patients needs for each group to maintain proper statistical power. In total 1300 subjects will be randomized. The primary endpoint analysis will be performed on ITT (Intention-To-Treat) population, by using two-sided superiority test with alpha = 0.05. Due to the short observation period (3 days ±2), a low number of missing data is expected. However, in case it exceeds 15-20%, missing, unused or spurious data will be considered using a tipping point analysis for each population. The comparaison in RAO rates between treatment groups will be tested by Chi-squared tests or Fisher's exact test, as appropriate. Odd-Ratio with IC95% will be calculated. Logistic regression analyses will be used to test the tendency.


Recruitment information / eligibility

Status Completed
Enrollment 1309
Est. completion date December 28, 2021
Est. primary completion date December 28, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient is at least 18 years of age. - Patient has provided written informed consent. - Patient is undergoing diagnostic coronary angiography and/or PCI. - Patient is willing to comply with all protocol-required evaluations during the hospitalization. - Patient is suitable for both DTRA and CTRA using 6Fr GSS. Exclusion Criteria: - Patient has a medical condition that may cause non-compliance with the protocol and/or confound the data interpretation. - Patients on chronic hemodialysis. - Patients presenting with ST-elevated myocardial infarction (STEMI). - Patients have chronic total occlusion (CTO) lesions in coronary artery.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Coronary angiography and or Percutaneous coronary Intervention
Radial access punture site

Locations

Country Name City State
Belgium UZ Brussel Brussel
Belgium Hôpital Civil Marie Curie Charleroi Hainaut
Belgium CHU Jolimont Haine-Saint-Paul Hainaut
Belgium Cliniques Universitaires Saint-Luc Woluwe-Saint-Lambert Bruxelles
Czechia Plzen Medical University Plzen
Germany University Hospital Johannes Wesling Klinikum Minden Minden
Hungary Bács-Kiskun Megyei Kórház Kecskemet
Italy Sant'Eugenio Hospital Roma
Italy Istituto Clinico Humanitas Rozzano
Japan Shonan Kamakura General Hospital Kanagawa
Netherlands Isala Hospital Zwolle
North Macedonia University Clinic of Cardiology, Skopje Skopje
Switzerland HUG Geneva Geneva
Switzerland Kantonsspital Baselland Liestal Liestal
United Kingdom Royal Stoke University Hospital Stoke-on-Trent
United Kingdom Sunderland Royal Hospital Sunderland

Sponsors (2)

Lead Sponsor Collaborator
Terumo Europe N.V. Cromsource

Countries where clinical trial is conducted

Belgium,  Czechia,  Germany,  Hungary,  Italy,  Japan,  Netherlands,  North Macedonia,  Switzerland,  United Kingdom, 

References & Publications (4)

Aminian A, Saito S, Takahashi A, Bernat I, Jobe RL, Kajiya T, Gilchrist IC, Louvard Y, Kiemeneij F, Van Royen N, Yamazaki S, Matsukage T, Rao SV. Comparison of a new slender 6 Fr sheath with a standard 5 Fr sheath for transradial coronary angiography and intervention: RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT), a randomised multicentre trial. EuroIntervention. 2017 Aug 4;13(5):e549-e556. doi: 10.4244/EIJ-D-16-00816. — View Citation

Corcos T. Distal radial access for coronary angiography and percutaneous coronary intervention: A state-of-the-art review. Catheter Cardiovasc Interv. 2019 Mar 1;93(4):639-644. doi: 10.1002/ccd.28016. Epub 2018 Dec 11. Review. — View Citation

Kiemeneij F. Left distal transradial access in the anatomical snuffbox for coronary angiography (ldTRA) and interventions (ldTRI). EuroIntervention. 2017 Sep 20;13(7):851-857. doi: 10.4244/EIJ-D-17-00079. — View Citation

Sgueglia GA, Di Giorgio A, Gaspardone A, Babunashvili A. Anatomic Basis and Physiological Rationale of Distal Radial Artery Access for Percutaneous Coronary and Endovascular Procedures. JACC Cardiovasc Interv. 2018 Oct 22;11(20):2113-2119. doi: 10.1016/j.jcin.2018.04.045. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Forearm radial artery occlusion (RAO) rate before discharge Forearm radial artery occlusion (RAO) rate before discharge measured with Doopler Ultrasound up to 5 days
Secondary Rate of successful sheath insertion Rate of successful sheath insertion obtained though eCRF question up to 2 days
Secondary Rate of access site crossover Rate of access site crossover - if the initial access point fails physician can perform the procedure using other access site of his/her choice This data point is captured on the eCRF up to 2 days
Secondary Total procedural time Total procedural time defined as the time between initiation of local anesthesia to sheath removal - information captured on the eCRF up to 2 days
Secondary Sheath insertion time Sheath insertion time recorded in the eCRF and defined as when puncture with the introducer needle first attempted until the time when introducer sheath is successfully inserted up to 2 days
Secondary Puncture site bleeding according to EASY criteria Puncture site bleeding according to EASY criteria up to 5 days
Secondary Overall bleeding according to BARC criteria Overall bleeding according to BARC criteria up to 5 days
Secondary Vascular access-site complication Vascular access-site complication documented on the eCRF. It is composed by the rate of vessel perforation after occlusion requiring intervention, arterial dissection, pseudoaneurysm, and local haematoma up to 5 days
Secondary Rate of radial artery spasm Rate of radial artery spasm captured in the eCRF. Radial arety spasm is defined as an inability to manipulate the guidewire or catheter in a smooth and pain-free manner and also as an inability to remove the sheath in a similar way at the end of the procedure up to 2 days
Secondary Rate of distal radial artery occlusion (dRAO) Rate of distal radial artery occlusion (dRAO) by doopler ultrasound and capture in the eCRF up to 5 days
Secondary Patent hemostasis was achieved or not (CTRA) by reverse barbeau test Patent hemostasis was achieved or not (CTRA) by reverse barbeau test up to 5 days
Secondary Time required to reach hemostasis Time required to reach hemostasis, captured on the eCRF and defined as the time between sheath removal to complete hemostasis up to 5 days
Secondary Pain associated with the procedure: Visual Assessment Scale (VAS) Pain associated with the procedure measured by the Visual Assessment Scale (VAS), a numeric rating scale. VAS is a 10 cm line with anchor statements on the left (no pain = 0) and on the right (worst possible pain = 10) up to 5 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Completed NCT05672862 - International Post-PCI FFR Extended Registry
Completed NCT04492423 - VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
Completed NCT01205776 - EXCEL Clinical Trial N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT00046410 - Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Completed NCT02948517 - Time Restricted Feeding for Weight Loss and Cardio-protection N/A
Not yet recruiting NCT02895009 - Hemostatic Compression Patterns After Transradial Coronary Intervention N/A
Completed NCT02784873 - High Intensity Interval Training in UK Cardiac Rehabilitation Programmes N/A
Recruiting NCT02859480 - Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI Phase 4
Withdrawn NCT02418143 - A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
Completed NCT02382731 - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT02248415 - Administration of Warm Blood Cardioplegia With or Without Roller Pump N/A
Recruiting NCT01207167 - Mediators of Atherosclerosis in South Asians Living in America
Completed NCT02088138 - Functional Electrical Stimulation in Cardiac Patients N/A
Completed NCT02173067 - Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective N/A
Completed NCT02133807 - Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis Phase 3